403 results about "Venous thromboembolic disease" patented technology

The present invention relates to methods and compositions for symptom-based differential diagnosis, prognosis, and determination of treatment regimens in subjects. In particular, the invention relates to methods and compositions selected to rule in or out venous thromboembolic disease, pulmonary embolism, and/or deep vein thrombosis, and for risk stratification in such conditions.

The invention provides a locally-plugged thrombus scaler, which comprises a core tube, a sleeve, a first saccule, a second saccule and a thrombus scraping skein, wherein the sleeve is sleeved outside the core tube in a movable way; the first saccule is connected to the head end of the core tube; the second saccule is sleeved outside an inner tube of the sleeve; and the thrombus scraping skein is sleeved outside the core tube in a movable way and is arranged in front of the sleeve. By the locally-plugged thrombus scaler, two saccules are expanded simultaneously to plug thrombus deposition positions on veins and form a section of closed space, and thrombus is crushed and scraped by rotating the thrombus scraping skein in the closed space. The locally-plugged thrombus scaler can scrape thrombus completely, prevent vein inner membranes from being injured, discharge the thrombus from human bodies completely and prevent crushed small thrombus blocks from remaining in the human bodies, is suitable for scraping venous thrombosis of limbs of the human bodies and is particularly suitable for scraping the thrombus at the deep positions of femoral veins of the human bodies by using a percutaneous microtrauma surgical technology.

The invention concerns the use of a mast cell activation- or degranulation-blocking agent in the manufacture of a medicament for the treatment of cerebral ischemia. The invention also relates to treatment of patients suffering from acute ischemic stroke, acute hemorrhagic stroke, subarachnoid hemorrhage, cerebral venous thrombosis or global cerebral ischemia associated with cardiac arrest. Further, the invention provides compositions of contrast media or similar exogenous media, which are intended for use in diagnostic or therapeutic applications for introduction into the intravascular, intrathecal or the intracranial space, comprising a mast cell degranulation-blocking and/or mast cell activation-blocking agent.

A compound represented by formula (1):

Q¹-Q²-T⁰-N(R¹)-Q³-N(R²)-T¹-Q⁴  (1)

[wherein R¹ and R² are hydrogen atoms or the like; Q¹ is a saturated or unsaturated, 5- or 6-membered cyclic hydrocarbon group which may be substituted, or the like; Q² is a single bond or the like; Q³ represents the following group:

(wherein Q⁵ is an alkylene group having 1 to 8 carbon atoms, or the like); and T⁰ and T¹ are carbonyl groups or the like], a salt thereof, a solvate thereof, or an N-oxide thereof.

The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after artificial valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), multiple organ dysfunction syndrome (MODS), thrombus formation during extracorporeal circulation, or blood clotting upon blood drawing.

The invention discloses an exercise instrument for preventing deep venous thrombosis of lower limbs. The exercise instrument for preventing deep venous thrombosis of lower limbs comprises a casing, the upper end of the casing is provided with two sliding grooves with corresponding positions, a measuring side wall of the casing is respectively provided with a first device chamber and a sliding plugchamber, the side wall of the casing is fixedly connected to a driving motor, one end of an output shaft of the driving motor located in the first device chamber is fixedly connected to a first bevelgear, the inner wall of the first device chamber is rotatably connected to a driving wheel, the side wall of the driving wheel is coaxially fixedly connected to a second bevel gear meshed with the first bevel gear, the upper end of the casing is provided with a first groove communicated with the first device chamber, and the inner walls of the two sliding grooves are rotatably connected to parallelly-arranged first reciprocating lead screws. The exercise instrument for preventing deep venous thrombosis of lower limbs can massage the foot sole and instep to achieve a function of stimulating limb nerves, an ankle joint is protected from stiffness deformation, the foot drop is effectively prevented, and the rehabilitation of a patient is promoted.

A device which combines pneumatic compression therapy and ultrasound based therapy for the prevention and treatment of thrombosis. Ultrasound transducers (11) are placed in specially designed pockets (12) in stockings (23) or leggings (25). This allows for convenient use of ultrasound therapy. Pneumatic compression is also carried out by air bladders (14) which are placed in leggings. The overall result is an easy to use device which should produce significantly better results in the prevention and treatment of thrombosis, ultimately reducing patient morbidity and mortality.

The present invention provides a positive pressure chamber for treating extremities, which is used for treating extremity swelling or edema, rehabilitation, prophylaxis for deep venous thrombosis, relieving extremity pain, improvement of extremity skin, and the like.

The invention discloses a (3S) -1, 1-Dihydroxymethyl-Tetrahydro-Beta-Carboline-3-Formyl-Gly-Arg-Gly-Asp-Val, discloses a preparation method thereof, discloses the anti-arterial thrombosis activity, discloses the anti-venous thrombosis activity, discloses the activity of inhibiting the GPIIb/IIIa expression, and discloses the activity of inhibiting the P-selectin expressionin vivo. Therefore, the invention discloses the application in preparing anti-arterial thrombosis medicine, the application in preparing the anti-venous thrombosis medicine, the application in preparing the GPIIb/IIIa antagonist and the application in preparing P-selectin antagonist. The formulas are shown in the decription.

The invention discloses a (3S) -1, 1-Dihydroxymethyl-Tetrahydro-Beta-Carboline-3-Formyl-Gly-Tyr-Ile-Gly-Ser-Lys, discloses a preparation method thereof, discloses the anti-arterial thrombosis activity, discloses the anti-venous thrombosis activity, discloses the activity of inhibiting the GPIIb/IIIa expression, and discloses the activity of inhibiting the P-selectin expression in vivo. Therefore,the invention discloses the application in preparing anti-arterial thrombosis medicine, the application in preparing the anti-venous thrombosis medicine, the application in preparing the GPIIb/IIIa antagonist and the application in preparing P-selectin antagonist. The formulas are shown in the decription.

The invention discloses a lower limb deep venous thrombosis thrombolysis curative effect prediction method and system based on machine learning. The method comprises the steps: obtaining an area of interest of lower limb deep venous thrombosis from an MRI image; Performing image omics feature extraction on the region of interest of the lower limb deep venous thrombosis; And predicting the curative effect of lower limb deep venous thrombosis thrombolysis by adopting a machine learning method according to an image omics feature extraction result. The invention discloses a lower limb deep venousthrombosis thrombolysis curative effect prediction method and system based on machine learning. lower limb deep venous thrombolysis curative effect prediction is performed through image omics featureextraction and a machine learning method; The MRI imaging omics method and the machine learning technology are combined to predict the thrombolysis curative effect of the deep venous thrombosis of the lower limbs, the curative effect evaluation work can be completed through prediction before thrombolysis treatment, the method does not depend on experience of doctors any more, and the thrombolysiscurative effect prediction result is more accurate and higher in efficiency. The method can be widely applied to the field of medical image processing.

The invention discloses a (3S) -1, 1-Dihydroxymethyl-Tetrahydro-Beta-Carboline-3-Formyl-Gly-Arg-Gly-Asp-Ser, discloses a preparation method thereof, discloses the anti-arterial thrombosis activity, discloses the anti-venous thrombosis activity, discloses the activity of inhibiting the GPIIb/IIIa expression, and discloses the activity of inhibiting the P- selectin expression in vivo. Therefore, theinvention discloses the application in preparing anti-arterial thrombosis medicine, the application in preparing the anti-venous thrombosis medicine, the application in preparing the GPIIb/IIIa antagonist and the application in preparing P- selectin antagonist. The formulas are shown in the decription.

The invention provides a portable pneumatic massager capable of resisting deep venous thrombosis of lower limbs, and relates to the technical field of rehabilitation instruments. The portable pneumatic massager capable of resisting deep venous thrombosis of the lower limbs comprises two sleeve cylinders which are bilaterally symmetrical, wherein a circle is slidably connected with and arranged ineach sleeve cylinder; an air bag is placed in each circle; sliding blocks are slidably connected with and arranged in each circle; an extrusion rod is fixedly connected with and arranged in each sliding block through a first spring; and a rolling ball is connected with and arranged at one side, close to the center of a circle, of each extrusion rod in a rolling mode. The portable pneumatic massager capable of resisting the deep venous thrombosis of the lower limbs has the following advantages: the effect of improving the hysteresis of a venous blood flow is achieved; the formation of the deepvenous thrombosis is prevented; the portable pneumatic massager can be applicable to patients with different leg sizes; the effect of relieving a deep venous blood flow is improved; the production cost of the massager is reduced; meanwhile, the portable pneumatic massager is small in size and light in weight; and the portable pneumatic massager is convenient to carry by adoption of the combined design of the sleeve cylinders and a treading seat.

The invention relates to a double-cavity-catheter self-sealing venous indwelling needle which consists of an indwelling catheter 1, a working liquid bag tube 2, an infusion tube cavity 3, a needle point groove 4, a flexible connecting tube 5, a pressuring block 6, a pressure-resistant liquid bag 7, lock catches 8, a needle seat 9 and a steel needle core 10 with a semicircular section. The double-cavity-catheter self-sealing venous indwelling needle is very simple to operate, tube sealing is finished under the condition that a working liquid is completely sealed, no pollutant enters, the needle can be used continuously without complications such as secondary injuries to veins, liquid leakage, phlebitis, venous thrombosis and the like, and a patient feels comfortable. Disposable syringes and flushers are not consumed, nursing operation steps are reduced, and the nursing efficiency and the nursing quality are improved.

The present invention provides novel proteins and peptides from the receptor binding region of human Growth Arrest Specific Gene 6 (Gas6) and antibodies, including specified portions or variants, specific for at least one such Gas6 peptide or fragment thereof. The aforesaid peptides can be used to generate human, primate, rodent, mammalian, chimeric, humanized and/or CDR-grafted anti-Gas6 antibodies. The invention also provides for the nucleic acids encoding such peptides and anti-Gas6 antibodies, complementary nucleic acids, vectors, host cells, and methods of making and using thereof, including therapeutic formulations, administration and devices. Fifteen novel peptide sequences from the Gas6 G domain that are implicated in Gas6 interactions with its receptors are identified, isolated, and synthesized so as to allow generation of anti-Gas6 antibodies. The peptide sequences include three ESTs that encompass regions predicted to contribute to receptor binding or that can raise anti-Gas6 antibodies. This invention provides for such antibodies to be used in modulating or treating at least one Gas6-related disease in a cell, tissue, organ, animal, or patient. Such diseases may include, but are not limited to, thromboembolic disease, ischemic disease, venous thromboembolism, arterial or venous thrombosis, pulmonary embolism, restenosis, diabetic angiopathy and allograft atherosclerosis.

The invention provides phascolosoma esculenta plasmin, which is extracted from phascolosoma esculenta, and has double activities of directly dissolving fibrin and kinase. The phychemical performance of the plasmin is that: the molecular weight is between 28,000 and 32,000, the isoelectric point is between 4.6 and 6.6, the dissolution activity of fibrin does not change greatly under a temperature range between 30 and 70 DEG C, and the stability range to the pH value is between 5.0 and 9.0. The phascolosoma esculenta plasmin has the direct fibrin and kinase dissolving activities, has simple extracting process, low preparation cost and easily obtained raw materials, can be developed into intravenous injection, contains the plasmin capable of directly dissolving thrombus, and is expected to obtain better effect in treating catheter assisted thrombolysis treating peripheral arterial occlusion and deep venous thrombosis.

The invention discloses an iliofemoral deep venous moniliform eccentric sacculus thrombolytic thrombolysis thrombectomy catheter and a using method of the iliofemoral deep venous thrombosis moniliform eccentric sacculus thrombolysis thrombectomy catheter. The tail end of the catheter is composed of two openings, wherein one is a sacculus catheter opening, and the other one is called a Y valve connector, is a common entrance of a guide wire for guiding and a thrombolysis catheter, and is used by being connected with a Y valve. A catheter end is a two-cavity catheter composed of two catheters in a fusing mode, wherein the two catheters are mutually independent in function, one cavity serves as a sacculus catheter passage, and the other cavity serves as a guide wire and thrombolysis catheter passage. A catheter working part is composed of moniliform eccentric sacculus and a corresponding crack thrombectomy catheter on the other side. Catheter cavities are made of a +PTEE hydrophilic coating. Each part of the sacculus and each part of thrombolysis (with the length of 10-20cm) can work respectively or simultaneously. Sacculus (with the diameter of 5-20mm) squeezes thrombectomy. Thrombectomy medicine thrombolysis can be simultaneously filled in the crack catheter on the other side. The crack catheter on the other side can rotate so as to improve thrombolysis thrombectomy effect.